| United States Patent |
5,905,265 |
| Gubernick , et al. |
May 18, 1999 |
The present invention provides a method of improving skin condition by
administering to the skin a physiologically acceptable substrate that is exposed
to a magnetic vector potential field and that optionally contains information
energy.
| Inventors: |
Gubernick; Joseph (New York, NY); Cioca;
Gheorghe (New York, NY) |
| Assignee: |
EL Management Corp. (New York, NY) |
| Appl. No.: |
646798 |
| Filed: |
May 21, 1996 |
| U.S. Class: |
250/492.1 |
| Intern'l Class: |
H01J 37//00 |
| Field of Search: |
250/492.1 |
References Cited [Referenced
By]
U.S. Patent Documents
| 5012110 |
Apr., 1991 |
Kropp |
250/492. |
| 5138172 |
Aug., 1992 |
Kropp |
250/492. |
| 5247179 |
Sep., 1993 |
Tachibana |
250/492. |
| 5543111 |
Aug., 1996 |
Bridges et al. |
250/492. |
Primary Examiner: Nguyen; Kiet T.
Attorney, Agent or Firm: Pennie & Edmonds LLP
Claims
1. A method of improving skin condition comprising the steps of:
a) exposing a physiologically acceptable substrate to a magnetic vector
potential field and directly applying information energy to the substrate while
the substrate is exposed to the magnetic vector potential field to produce a
substrate that contains information energy; and
b) administering to the skin the substrate that contains information energy,
resulting in increased protein synthesis by the skin.
2. The method of claim 1 where at least one Wekroma Rod selected from the group
consisting of 1200.7, 622, 232, 7509, 326, 329, Fibro 1, and Fibro 2 is used to
directly apply information energy to the substrate.
3. The method of claim 2 where at least one Wekroma Rod No. 232 is used to
directly apply information energy to the substrate.
4. The method of claim 3 wherein the substrate is at least once passed through a
Wekroma Bio-Transfer device that produces the magnetic vector potential field
and that contains at least one Wekroma Rod No. 232.
5. A method of improving skin condition comprising the steps of:
a) exposing a physiologically acceptable substrate to a magnetic vector
potential field; and
b) administering to the skin the exposed substrate, resulting in increased
protein synthesis by the skin.
6. The method of claim 5 or 1 further resulting in increased collagen content of
the skin.
7. The method of claims 5 or 1 wherein the substrate is in the gaseous, liquid,
solid or liquid crystalline phase.
8. The method of claim 7 wherein the substrate is in the liquid or liquid
crystalline phase.
9. The method of claim 8 wherein the substrate is in the liquid phase.
10. The method of claim 8 wherein the liquid phase comprises water.
11. The method of claim 10 wherein the liquid phase comprises sodium chloride
and magnesium chloride.
12. The method of claim 10 wherein the liquid phase comprises iron ions and
calcium ions.
13. The method of claims 5 or 1 wherein the magnetic vector potential field is
produced by two opposite sets of magnets, each said set of magnets comprising a
plurality of magnets arranged side by side, with alternating N and S poles,
wherein the substrate is exposed to a magnetic vector potential field when the
substrate is placed between the opposing sets of magnets.
14. The method of claim 13 wherein the substrate is at least once passed through
a Wekroma Bio-Transfer device.
Description
FIELD OF THE INVENTION
The present invention relates to the field of homeopathic treatments, and more
particularly, to the use of a physiologically acceptable substrate containing
information energy for cosmetic and medical applications.
BACKGROUND OF THE INVENTION
Homeopathy has been
explained as copying information, e.g., a pattern or a combination of
oscillations of different frequencies, onto a substrate from the information or
pattern existing in the molecular structure of natural substances, e.g., herbs,
antibodies, or pollen. The substrate with the copied information or pattern
incorporated therein can then be used to effect a desired response. For example,
in homeopathic medicine, the desired response might be the reduction of allergy
symptoms in hay fever sufferers.
U.S. Pat. No. 5,138,172 of K. E. Werner Kropp teaches a method for applying
information energy to a substrate such as saline solution or oil by exposing the
substrate to a magnetic vector potential field. U.S. Pat. No. 5,012,110 of K. E.
Werner Kropp teaches a process for the manufacture of a synthetic homeopathic
substrate by placing the substrate between opposing sets of magnets.
French patent application, Publication No. 2,634,381, published Jan. 26, 1990
and WO 91.10450, published Jul. 25, 1991 of J. J. C. Morez teach a method of
producing larger quantities of homeopathic medicine by transferring to a large
mass of material such as water the electromagnetic information of a homeopathic
remedy by way of a transmitter-receiver.
An object of the present invention is to provide a novel method of using
physiologically acceptable substrates containing information energy for use in
cosmetics, e.g. for improving skin condition.
Another object of the present invention is to provide a novel method of using
physiologically acceptable substrates containing information energy for use in
homeopathic medicine.
SUMMARY OF THE INVENTION
The invention is related to the use of substrates such as aqueous salt
solutions, massage oils or other pharmaceutically acceptable carriers that have
been exposed to information energy such as oscillation patterns modeled after
those found in natural herbs. In general, the substrate can be in the gaseous,
liquid, solid or liquid crystalline phase. The aqueous salt solutions may
contain sodium chloride and magnesium chloride; as well as dissolved iron and
calcium ions.
The substrates that contain information energy can be used to improve skin
condition by topically administering the substrates to skin. By skin condition,
we mean, without limitations, dry skin, xerosis, ichthyosis, dandruff, brownish
spots, keratoses, melasma, lentigines, age spots, liver spots, pigmented spots,
wrinkles, blemishes, skin lines, oily skin, acne, warts, eczema, pruritic skin,
psoriasis, inflammatory dermatosese disturbed keratinization, skin changes
associated with aging, nail or skin requiring cleansers, conditioning or
treatment, and hair or scalp requiring shampooing or conditioning.
The present invention provides a specific method of increasing proline uptake in
human dermal fibroblast cells by contacting the cells with a physiologically
acceptable substrate that contains information energy.
Increased proline uptake is an indication of the collagen synthesis of these
cells--a desirable cosmetic benefit which is one route of improving skin
condition. Fibroblast cells, which are located in the dermis, perform many
functions, i.e., synthesize collagen, elastin, glycoseaminoglycans (GAGS), to
name a few. Proline is an amino acid which is an integral part of the collagen
structure. By demonstrating an increase in the total amount of proline uptake,
we demonstrate an increase in the total amount of collagen synthesized. Collagen
and elastin are two proteins found in the dermis responsible for the firmness
and elasticity of the skin. Young, healthy skin has an abundance of these two
proteins. As the body ages, the process of synthesizing these proteins
decreases. Therefore, the total amount of collagen/elastin diminishes in older,
less healthy skin. Increasing the amount of collagen/elastin in the dermis by
the present invention leads to improvement in skin condition.
The present invention further provides a specific method of producing the
physiologically acceptable substrate that contains information energy. The
method is generally described in U.S. Pat. Nos. 5,012,110 and 5,138,172 of K. E.
Werner Kropp and comprises imparting information energy of desired frequencies
to a substrate that has been placed in a specific configuration within a
magnetic field, called a magnetic vector potential field. The apparatus for
applying the information energy to the substrate may comprise
a) two opposite sets of magnets, each said set of magnets comprising a plurality
of magnets arranged side by side, with alternating N and S poles, wherein the
substrate is exposed to a magnetic vector potential field when the substrate is
placed between the opposing sets of magnets; and
b) a means for applying information energy to the substrate when the substrate
is located in the magnetic vector potential field.
The application of information energy to the substrate may be accomplished by
exposing the substrate to the following Wekroma rods having the following
properties:
1200.7 Antioxidants BHT N-acetyilcystine Beta Caratene
622 Cellulite
232 Revitalization Collagen Synthesis, Balancing Rods
7509 Neutralize Free Radicals
326 Inhibit Bacterial Growth
329 Inhibit Bacterial Growth
Fibro 1 stimulate fibroblast calls
Fibro 2 Stimulate fibroblast cells
Preferably, the substrate is exposed to the above Wekroma Rods by the use of a
Wekroma Bio-Transfer device, wherein the substrate is at least once passed
through such device. The substrate may be exposed to the rods individually or in
combination.
The present invention additionally provides a method of improving skin condition
comprising a) exposing a physiologically acceptable substrate to a magnetic
vector potential field; and b) administering to the skin the exposed substrate.
Thus, exposure of a substrate to a magnetic vector potential field, such as the
sets of magnets described above without application of information energy is
sufficient to obtain a treated substrate capable of improving skin condition.
One preferable way of treating the substrate with a magnetic vector potential
field is to pass the substrate at least once through the Wekroma Bio-Transfer
device, without the placement of any Wekroma Rods within the device.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts the Bio-Transfer device available from Wekroma-Vertrieb Schweiz.
FIG. 2 depicts graphically the increase in proline level in Human Dermal
Fibroblast calls upon increasing the concentration of the Body Booster mineral
water that was treated with the Wekroma Bio-Transfer device.
FIG. 3 is a diagrammatic perspective view of an apparatus for conducting ate
processes according to the invention, wherein the permanent magnets are
subdivided into individual striplike magnets with alternating North-South poles.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The manner in which a substrate is exposed to information energy is generally
described in U.S. Pat. No. 5,138,172 of K. E. Werner Kropp; U.S. Pat. No.
5,012,110 of K. E. Werner Kropp, French patent application, Publication No.
2,634,381 of J. J. C. Morez, and WO 91,10450 of J. J. C. Morez. The substrate is
generally in a gaseous, liquid, solid or liquid crystalline phase.
One arrangement for exposing aqueous solutions to information energy is by use
of a Wekroma Bio-Transfer device, purchased from Wekroma-Vertrieb Schweiz, Beat
Lanz, 6313 Menzingen, Federal Republic of Germany. Rod No. 232 as supplied by
Wekroma was placed in the Wekroma Bio-Transfer device as shown in FIG. 1. Test
tubes containing aqueous solutions were passed through the Bio-Transfer device
by way of a channel opening. The residence time the solution is in the
Bio-Transfer device does not appear to be critical, typically ranging from less
than one second to a few seconds. The rate at which the test tubes pass through
the Bio-Transfer device is typically the speed at which they free fall. Both
residence time and rate of pass through may be controlled by having the solution
pump through the Bio-Transfer device at a certain controlled velocity.
The basic arrangement for the treatment of liquids as substrates with a
variation in the absorption properties thereof in a magnetic field is shown in
FIG. 3. The magnetic field strength Ha is produced by permanent magnets 2 and 3
which are disposed in mutually opposite relationships in an opposite-pole
configuration, on non-magnetic support 5. Disposed approximately in the middle
of the arrangement is a glass vessel 6 with a substrate 4 to be treated, in the
form of a liquid. The respectively selected information energy is supplied to
the liquid in the glass vessel 6, perpendicularly to the orientation of the
magnetic field Ha, by way of a probe So or 8, 7. In that connection, the glass
vessel 6 may also be closed.
The magnetic longitudinal axes A and B of the two permanent magnets 2 and 3 are
oriented in the same direction relative to each other. The probe So may be
brought in either beside the substrate 4 or the vessel thereof (FIG. 3; 8) or
through the non-magnetic support 5 to the substrate, from below (FIG. 3; 7). The
information energy is supplied to the probe So by way of the connection 9.
In the embodiment shown, each individual magnetic strip 50 is also opposed by
the alternative pole. By the use of a parallel swinging effect (see arrows 51),
such polarity arrangement can be easily changed, for example, by arranging the
same poles facing each other. Such a sidewise, offset, swinging, pole-changing
arrangement can be performed even with high frequencies.
The arrows Lx vert(ical) and Lx hor(izontal) demonstrate the penetration
direction of a laser beam as the carrier of the information.
EXAMPLE 1
The following demonstrates how aqueous saline solution treated with the Wskroma
Bio-Transfer device can stimulate proline uptake by Human Dermal Fibroblast
cells.
1. To 99.2 grams of sterile distilled water add 0.4 grams of Sodium Chloride and
0.4 grams of Magnesium Chloride. Stir at room temperature until the solids
dissolve and a clear solution is obtained.
2. The solution obtained in Step 1 was split into 5 equal aliquots and stored in
sterile test tubes.
3. Sample No. 1 was left untreated; to be used as a control to compare to the
other treated samples.
4. Rod No. 232-1 (as supplied by Wekroma) was placed in the Wekroma Bio-Transfer
device as shown in the accompanying drawing FIG. 1.
5. One of the test tubes containing the sterile salt solution was then passed
through the Bio-Transfer as depicted in the accompanying drawing. This procedure
was repeated two times. Then the sample was set aside.
6. Then Rod No. 232-1 was removed from the Bio-Transfer and Rod No. 232-2 was
placed in the Bio-Transfer. Another of the test tubes containing the sterile
salt solution was passed through the Bio-Transfer as in Step No. 5.
7. Repeat the above procedure until the remaining test tubes were treated,
(Sample No. 4) was treated with Rod No. 232-3 and Sample No. 5 was treated with
Rod No. 232-4). Rods No. 232-1, 2, 3 and 4 are identical replicas of each other.
8. All samples were submitted for proline uptake testing.
The results indicate that all samples showed increases over the media control.
Wekroma treated salt solutions (Samples Nos. 2 and 5) showed statistically
significant increases over Sample No. 1 (salt solution, untreated by the Wekroma
Bio-Transfer device).
The protocol for the proline uptake testing is as follows. Two confluent 24-well
plates were treated with the sample solutions. The untreated salt solution
control was added neat in 1, 5, and 10% concentrations Solutions of the same
material was passed through Rod No. 232 and assayed at the same concentrations
as the control. Each sample was assayed in triplicate. The samples were then
labeled with 1 .mu.Ci/ml Of .sup.3 H Proline by adding 1 .mu.l to each ml well.
Plates were incubated over a five day period, in which time the treatment
procedure was repeated. After treatment incubation was complete, the plates were
assayed for total protein uptake. Each plate was washed with 1 ml of ice cold
PBS and then 1 ml of ice cold TCA for 10 minutes. TCA washes were repeated twice
for five minutes each. Each plate was then washed with 1 ml of MeOH and allowed
to dry. Protein was then solubilized in 0.3M NaOH and gently shaken for 0.5
hours. Supernatant is collected and added to scintillant, and measured on the
liquid scintillation counter.
EXAMPLE 2
The following demonstrates how a specific mineral water treated with the Wekroma
Bio-Transfer device can stimulate proline uptake by Human Dermal Fibroblast
cells.
Body Booster mineral water having the composition listed in Table 1 was treated
in a Wekroma Bio-Transfer device using a Wekroma Rod No. 232 as described in
Example 1.
Three confluent 24-well plates were labelled with 1 .mu.ci/ml of .sup.3 H
Proline prior to the addition of the mineral water. Tests were conducted with
the Body Booster mineral water that was treated with the Wekroma Bio-Transfer
device, using the untreated mineral water as a control.
Each sample was assayed in triplicate using 0.1, 0.5 and 1% concentrations
Plates were incubated over the weekend before being assayed for total protein.
At this time each plate was washed with 1 ml of ice cold PBS, and then 1 ml of
ice cold TCA for 10 minutes TCA washes were repeated twice for five minutes
each. Each plate was then washed with 1 ml of MeOH and allowed to dry. Protein
was then solubilized in 0.3M NaOH containing 1% SDS and gently shaken for 0.5
hours. Supernatant is collected and added to scintillant, and measured on the
liquid scintillation counter.
An increase in protein count was observed for the Wekroma treated Body Booster
mineral water. A dose dependent increase occurred in which the 0.1, 0.5, and 1%
concentrations increased protein by 3, 17, and 27%, respectively. See Table 2
and FIG. 2. The results for the 0.5 and 1% doses were statistically significant
with p-values of 0.02 and 0.03, respectively.
EXAMPLE 3
The following demonstrates that Body Booster mineral water by itself increases
proline uptake However, treatment of this mineral water with the Wekroma
Transfer device using Rod No. 232 as outlined in Example 1 resulted in higher it
proline uptake compared to the untreated mineral water control. Treatment of
this mineral water with the Wekroma Transfer device using Rod No. 1200.7 did not
increase proline uptake beyond the control.
Two confluent 24-well plates were treated with the following: various different
treatments of Body Booster consisting of Wekroma Rods Nos. 232 and 1200.7. The
Body Booster control was added neat in 1, 5, and 10% concentrations. The same
material was passed through Rods Nos. 232 and 1200.7 and assayed at the same
concentrations Each sample was assayed in triplicate. The samples were then
labeled with 1 .mu.Ci/ml of .sup.3 H Proline by adding 1 .mu.l to each ml well.
Plates were incubated over a five day period, in which time the treatment
procedure was repeated. After treatment incubation was complete, the plates were
assayed for total protein uptake. Each plate was washed with 1 ml of ice cold
PBS, and then 1 ml of ice cold TCA for 10 minutes TCA washes were repeated twice
for five minutes each. Each plate was then washed with 1 ml of MeOH and allowed
to dry. Protein was then solubilized in 0.3N NaOH and gently shaken for 0.5
hours. Supernatant is collected and added to scintillant, and measured on the
liquid scintillation counter.
Body Booster increased uptake 52% when treated with Rods 232, yielding a 12%
increase from the untreated groups, while 1200.7 treatment paralleled the
untreated group. Student's t-test indicated that all the materials were
statistically significant. See Table 3.
EXAMPLE 4
We repeated earlier experiments which showed that Body Booster mineral water
increased proline incorporation Body Booster mineral water without any
information transferred to it, increased proline uptake by 44, 38, and 33% at 1,
5, and 10% concentrations. See Table 4. In this experiment, information
transferred with Nekroma Rods No. 1200.7 displayed a statistically significant
increase of 16% at a 10% dosage.
Two confluent 24-well plates were treated with Body Booster mineral water that
received 10 passes with Wekroma Rods No. 1200.7. The Body Booster mineral water
control was added neat in 1, 5, and 10% concentrations. The same material was
passed through Rods No. 232 and assayed using the equivalent concentrations. TGF
.beta. (10 ng/ml) was assayed as a positive control. Each sample was assayed in
triplicate The samples were then labeled with 1 .mu.Ci/ml of .sup.3 H Praline by
adding 1 .mu.l to each 1 ml well. Plates were incubated over a five day period,
in which time the treatment procedure was repeated. After treatment incubation
was complete, the plates were assayed for total protein uptake. Each plate was
washed with 1 ml of ice cold TCA for 10 minutes. TCA washes were repeated twice
for five minutes each. Each plate was then washed with 1 ml of MeOH and allowed
to dry. Protein was then solubilized in 0.3M NaOH and gently shaken for 0.5
hours. Supernatant was collected and added to scintillant, and measured on the
liquid scintillation counter.
TGF .beta. displayed increases of 63%, and 87% (P(0.003). Body Booster mineral
water increased uptake 44, 38, and 33% as a control at 1, 5, and 10%
concentrations Body Booster mineral water treated with Rods No. 1200.7
(antioxidant) displayed increases of 6 and 16% at 5 and 10% concentrations
respectively, when compared to Body Booster mineral water controls. Student's
t-test conveyed statistical significance for all materials, when values were
compared to untreated controls. Statistical analysis, compared to Body Booster
mineral water control, yielded values greater than 0.05 excluding the 10%
concentration that had been treated with Rod No. 120307
EXAMPLE 5
The following experiment showed that aqueous solutions so of sodium chloride and
magnesium chloride treated with Wekroma Rod 232 increased collagen production by
Normal Human Dermal Fibroblasts cells ("NHDF") to a significant degree
compared to the control aqueous solution containing the same concentration of
salts but untreated with the Wekroma Rod 232. The ability of the treated aqueous
solutions to increase collagen production was retained upon storage of at least
six months.
Five salt solutions of 0.4% NaCl and 0.4% MgCl.sub.2 in deionized water were
made. One solution (3249/1) was not treated with Wekroma Rod 232 and used as the
control solution. The remaining four salt solutions (3249/2-3249/5) were treated
with Nekroma Rod, 232-1, 232-2, 232-3, and 232-4 respectively. All of these
Wekroma Rods are identical replicas of each other. All five salt solutions were
assayed at three different doses (1, 5 and 10% in deionized water) for any
increase in the production of collagen by NHDF cells.
All sample solutions showed increases, of varying degrees, over the media
control (see % change column in Table 5). Wekroma treated salt solutions 3249/2
and 3249/5 showed statically significant increases, over 3249/1, in the amount
of collagen released by KHDF cells in culture. 3249/1, the untreated control
solution, showed increases in collagen production (over the media control).
The four salt solutions treated with the Wekroma Rod's 232 were sealed and
stored under ambient conditions for six months and then reassayed for their
ability to increase the production of collagen by NHDF cells. These
"retained solutions" were also compared to stored solutions that were
retreated with the Wekroma Rods 232 (labeled as "remake solutions").
The results of the assay of the control salt solution, retained solutions and
remake solutions are shown in Table 6.
Collagen levels were not enhanced by the presence of 10% of the control salt
solution (MgCl.sub.2 and NaCl.sub.2 in deionized H.sub.2 O). Media containing
10% remake solution treated with #232-Rod 4 resulted in a 36% increase in
absolute collagen level, and a 6% decrease in DNA, combining to yield an overall
increase in Collagen/DNA of 43% over the control salt solutions Retain solution
originally treated with #232-Rod 4, when present at 10% concentration, yielded
an increase of 14% in absolute collagen levels along with a 24% decrease in DNA,
combining to yield an overall increase in Collagen/DNA of 50%. In contrast,
Mimosa pudica, used as a positive control, increased absolute collagen level by
20%, and decreased DNA by 65%, which resulted in an overall increase in
Collagen/DNA of 238%.
Of the sample solutions tested, the only ones to show substantial increases in
collagen levels were the remake solution treated with #232-Rod 4 and the retain
solution treated with #232 Rod-4. These samples yielded increases of 43 and 50%
respectively (over the salt solution control). In this assay, the positive
control, Mimosa pudica (@ 50 .mu.g/ml), yielded an increase of 238% over the
media control.
The following outlines the method used in the above two to determine collagen
and DNA levels.
NHDF cells were seeded and grown to confluence in a 96 well plate prior to being
treated with the Wekroma samples (n=3). Mimosa pudica (@ 50 .mu.g/ml) was added
as a positive control and media alone served as the negative control. The plate
was incubated for 4 days at 37.degree.C./5% CO.sub.2 before the supernatants
were harvested, and stored at -70.degree. in siliconized tubes until the ELISA
was performed.
The collagen ELISA was performed as follows:
A 96 well enzyme immunoassay grade microliter plate is coated, overnight at
4.degree. C., with an optimal amount of Human Type 1 collagen. In a separate
microliter plate (low protein binding) equal volumes of primary antibody (Rabbit
anti Human Type 1 Collagen) is mixed with either the collagen standards or the
unknowns and allowed to react overnight at 4.degree. C. (Inhibition Step). The
collagen standards or the collagen present in the unknowns will bind with the
primary antibody, leaving some of the primary antibody unbound.
The collagen coated plate is then washed extensively with Phosphate Buffered
Saline containing 0.05% Tween-20 (PBST)e dried and blocked with PBS containing
3% Bovine Serum Albumin for 1.5 hours at 37.degree. C. The blocking solution is
then removed from the wells, the plate is dried and the contents of the wells
containing the primary antibody/standard or unknown solution are transferred to
the blocked, collagen coated plate. The plate is incubated for 30 minutes at
room temperature, to allow whatever primary anti-body is left unbound to free
collagen, to bind to the collagen coating the plate. After the 30 minute
incubation, the solution is discarded. Discarded in the solution will be the
primary antibody bound to free collagen (from the standards or unknowns) Any
primary antibody that did not bind to collagen during the inhibition step will
be free to bind to the collagen coating the wells. If there was a lot of
collagen present in the standard or unknown solution, most of the primary
antibody will be bound up and not be available to bind to the collagen coating
the wells.
The primary antibody bound to the collagen coating the well is detected by the
addition of a goat anti-rabbit lgG-Alkaline Phosphatase conjugated antibody and
incubating for 1.5 hours at room temperature followed by extensive washing with
PBST. The alkaline phosphatase present in the wells is detected by the addition
of p-Nitrophenyl Phosphate as a substrate and the optical densities are read at
405 nM on a Molecular Devices microplate reader. A standard curve is constructed
and the collagen levels of the unknowns are determined from this curve.
The DNA assay was performed as follows. DNA levels are determined by performing
a freeze/thaw lysis of the cells in the presence of water and adding Hoechst
33258 (a dye that binds to DNA and becomes fluorescent) The plate is then read
on the spectrophotometer and DNA levels are calculated from the standard curve.
EXAMPLE 6
It is possible to produce a substrate treated only with a magnetic vector
potential field without the application of any information energy. This can be
accomplished by, for example, passing a solution through the Wekroma
Bio-Transfer device without the placement of any rods within the device. Such a
treated substrate is capable of improving skin condition upon administration of
the substrate to the skin.
It should be apparent to one of ordinary skill that other embodiments not
specifically disclosed nonetheless fall within the scope and spirit of the
present invention. Hence, the descriptions herein should not be taken as
limiting the invention in any way, except as stated in the following claims.
All references cited above are hereby expressly incorporated by reference.
TABLE 1
______________________________________
Composition Of Body Booster Mineral Water
______________________________________
Aluminum
1-10%
Arsenic 0
Antimony
0
Barium 0
Beryllium
0.01-0.1%
Boron 0.01-0.1%
Bismuth 0
Cadmium 0
Calcium 10-100%
Chromium
0
Cobalt 0
Copper 0.01-0.1%
Iron 0.01-0.1%
Lead 0
Lithium 0
Magnesium
1-10%
Manganese
1-5%
Mercury 0
Molybdenum
0
Niobium 0
Nickel 0.01-0.1%
Phosphorus
0
Potassium
0
Sodium 0.1-1.0%
Silicon 0.01-1.0%
Silver 0
Strontium
0.1-1.0%
Tantalum
0
Tellurium
0
Tin 0
Titanium
0.01-0.1%
Tungsten
0
Vanadium
0
Zinc <0.01%
Zirconium
0
______________________________________
TABLE 2
______________________________________
MATERIAL average DPM % change
P-value
______________________________________
untreated
control 29666.67
Fe H2O 0.10% 30266 2.020225
0.50% 28933.33 -2.47191
1% 31395 5.825843
treated control 26077.33
Fe H2O 0.10% 26974.33 3.439769
0.49
0.50% 30508.67 16.99305
0.02
1% 33053.33 26.7512 0.03
______________________________________
TABLE 3
______________________________________
% change
avg. P- from BB
dpm dpm % change value
control
______________________________________
BB-control
1% 105215
110134 109543.3
34.19933
0.001
113281
5% 95021
117246 107548.3
31.75529
0.02
110378
10% 95786
99194 98260.33
20.37675
0.001
99801
BB-232 1% 111191
125587 123668.3
51.50358
0.003
12.89444
134227
5% 122170
110580 117679 44.16617
0.001
9.419641
120287
10% 95146
104946 100037 22.55331
0.004
1.808122
100019
BB-12007
1% 104023
112237 109372.3
34.08511
0.002
-0.1561
111857
5% 109353
108673 113090.7
38.64361
0.003
5.153342
121246
10% 106709
100710 96776.33
18.64304
0.12 -1.51027
82910
______________________________________
TABLE 4
__________________________________________________________________________
dpm minu
P-value
dpm avg. dpm
% change
P-value
avg.contro
among BB
__________________________________________________________________________
control 36335
30925
32558
30414
TGF B 51288
58159
53015.67
62.83453
0.003
49600
BB-C 1% 48752 16194
44941
46925
44.1274
0.003
12383
47082 14524
5% 49367 16809
41801
44988.33
38.17904
0.01
9243
43797 11239
10%
39432 6874
50542
43245.67
32.82655
0.06
17984
39763 7205
BB-232
1% 41992 9434
46412
45608
40.08231
0.01
13854
0.58
48420 15862
5% 45920 13362
44642
46858.33
43.92264
0.005
12084
0.54
50013 17455
10%
44162 11604
43276
43928.67
34.92434
0.004
10718
0.86
44348 11790
control 28578
25524
29228.67
33584
TGF B 51548
57206
54718.33
87.20776
0.001
55401
BB-1200.7
1% 44480 15251.33
42907
42945.33
46.92881
0.005
13678.33
0.67
41449 12220.33
5% 45415 16186.33
52041
47527.33
62.6052
0.005
22812.33
0.14
45126 15897.33
10%
49850 20621.33
49835
50052.33
71.24398
0.001
20606.33
0.05
50472 21243.33
__________________________________________________________________________
TABLE 5
______________________________________
PRODUCTION OF COLLAGEN BY NHDF CELLS
EXPOSED TO SAMPLE SOLUTIONS
Sample pg/ml +/- S.D.
% Change p value
______________________________________
3249/1
Control salt
solution
10% 2.5 +/- 0.02 4.2
5% 2.7 +/- 0.03 12.5
1% 2.6 +/- 0.01 8.3
3249/2
10% 3.0 +/- 0.06 25 0.02
5% 2.8 +/- 0.07 17 0.1
1% 2.4 +/- 0.12 0 0.8
3249/3
10% 2.6 +/- 0.02 8.3 0.1
5% 2.7 +/- 0.06 12.5 0.2
1% 2.8 +/- 0.11 17 0.2
3249/4
10% 2.7 +/- 0.09 12.5 0.1
5% 2.7 +/- 0.09 12.5 0.8
3249/5
10% 3.5 +/- 0.04 46 0.002
5% 3.0 +/- 0.05 25 0.02
TBF.beta. 3.0 +/- 0.02 25
Media Control
2.4 +/- 0.01
______________________________________
TABLE 6
__________________________________________________________________________
PRODUCTION OF COLLAGEN BY NHDF CELLS
EXPOSED TO RETAIN AND REMAKE SOLUTIONS
Sample
Coll (.mu.g/ml)
% Change
DNA (.mu.g/ml)
% Change
Coll/DNA
% Change
__________________________________________________________________________
Media
0.15 +/- 0.001
6.2 +/- 0.3 0.024
M. 0.18 +/- 0.008
+20 2.2 +/- 0.1
-65 0.081
238
pudica
Control
0.14 +/- 0.006
5.0 +/- 0.11
0.028
salt
soln.
#232-
0.19 +/- 0.015
+36 4.7 +/- 0.08
-6 0.040
+43
Rod 4
remake
#232-
0.16 +/- 0.023
+14 3.8 +/- 0.09
-24 0.042
+50
Rod 4
retain
#232-
0.15 +/- 0.012
+7 4.6 +/- 0.07
-8 0.033
+18
Rod 1
retain
#232-
0.14 +/- 0.018
0 6.5 +/- 0.02
+30 0.021
-25
Rod 2
retain
#232-
0.15 +/- 0.015
+7 5.2 +/- 0.07
+4 0.029
+3
Rod 3
retain
#232-
0.16 +/- 0.01
+14 4.6 +/- 0.12
-8 0.035
+25
Rod 3
remake
BQ 0.14 +/- 0.002
0 4.4 +/- 0.06
-12 0.032
+14
Rod
BQ-
DAT-C4
__________________________________________________________________________
* * * * *
